ClinicalTrials.gg
CompletedNCT02670551Updated Jan 30, 2019Results posted

Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression

A Phase 3 interventional study of Cariprazine and Placebo in Bipolar Disorder and Depression, sponsored by Forest Laboratories. Completed at 74 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-01-30.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
488
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Bipolar Disorder by AbbVie — 2 open to participants now, 2 under way, none of them phase 3. Bipolar Disorder · AbbVie.

Enrollment
3rd of 11
488 · median 234
Started
2016
with 1 other
Phase 3
3 of 11
none open now
Registered
6th of 11
by date

Among the 11 studies in Bipolar Disorder by AbbVie, this one is the 3rd largest by enrollment, is one of 2 that started in 2016, is one of 3 in phase 3, and was the 6th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 11 studies in Bipolar Disorder by AbbVie are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Bipolar Disorder by AbbVie, or all of them as a file.
02

Study summary

This study investigates the efficacy of a fixed-dose regimen of cariprazine 1.5 milligram (mg)/day or 3 mg/day compared to placebo for treatment of the depressive episode in participants with bipolar I disorder. The safety and tolerability of the fixed-dose regimens will be evaluated.

03

Conditions studied

  • Bipolar Disorder
  • Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently meet the , Fifth Edition (DSM-5) criteria for bipolar I disorder without psychotic features confirmed by the administration of the Mini International Neuropsychiatric Interview (MINI), with a current major depressive episode of at least 4 weeks and not exceeding 12 months in duration
  • Currently treated as an outpatient at the time of enrollment
  • A verified previous manic or mixed episode. Verification must include one of the following sources: --Treatment of mania with an anti-manic agent (eg, lithium or divalproate) or antipsychotic medication with an approved indication for mania --Hospital records/Medical records --Participant report corroborated by caretaker or previous or current treating clinician
  • 17-item Hamilton Depression Rating Scale (HAMD-17) total score ≥ 20
  • HAMD-17 item 1 score ≥ 2
  • Clinical Global Impressions-Severity (CGI-S) score ≥ 4
  • Negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test (women of only)
  • Normal physical examination, clinical laboratory test results, and (ECG) results or abnormal findings that are judged not by the Principal Investigator (PI)

Exclusion criteria

Exclusion Criteria:

  • Young Mania Rating Scale (YMRS) total score > 12
  • Four or more episodes of a mood disturbance (depression, mania, hypomania, or mixed state) within the 12 months before Visit 1
  • Any current axis 1 psychiatric diagnosis other than bipolar disorder with the exception of specific phobias
  • History of meeting criteria for: ○ Dementia, amnesic, or other cognitive disorder ○ Schizophrenia, schizoaffective, or other psychotic disorder

    ○ Mental retardation - DSM-5-based diagnosis of borderline or antisocial personality disorder or other axis II disorder of sufficient severity to interfere with participation in this study

  • History of meeting DSM-5 criteria for alcohol or substance abuse or dependence (other than nicotine or caffeine) within the 6 months before Visit 1
  • Positive result on blood alcohol test or urine drug screen for any prohibited medication. Exception: ○ Participants with a positive cannabinoid on entry may be retested before randomization. If the participant remains positive, the participant is no longer eligible ○ Participants positive for opiates on entry, discussion with Study Physician is required.
  • Electroconvulsive therapy in the 3 months before Visit 1
  • Previous lack of response to electroconvulsive therapy
  • Treatment with a depot antipsychotic drug within 1 treatment cycle before Visit 1
  • Treatment with clozapine in a dose of > 50 mg/day in the past 2 years
  • Prior participation in any study of RGH-188 or cariprazine within the past 12 months
  • Previous treatment with vagus nerve stimulation or transcranial magnetic stimulation within 6 months before Visit 1
  • Prior participation with any clinical trials, involving experimental or investigational drugs, within 6 months before Visit 1 or during the study
  • Initiation or termination of psychotherapy for depression within the 3 months preceding Visit 1, or plans to initiate, terminate, or change such therapy during the course of the study.
  • Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
  • Gastric bypass or any condition that would be expected to affect drug absorption (lap band procedures are acceptable if there is no problem with absorption)
  • Known history of cataracts or retinal detachment
  • Known infection
  • Employee, or immediate relative of an employee, of the Sponsor, any of its affiliates or partners, or the study center
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
488 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Following a 7 to 14 days screening/washout period, placebo-matching cariprazine capsule, one per day, orally for 6 weeks.

    Drug: Placebo

  • Experimental
    Cariprazine 1.5 mg

    Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligram (mg) capsule, one per day, orally for 6 weeks.

    Drug: Cariprazine

  • Experimental
    Cariprazine 3.0 mg

    Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day for 2 weeks followed by cariprazine 3.0 milligram (mg) capsule, one per day, orally beginning on Day 15 for 4 weeks.

    Drug: Cariprazine

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Week 6

    The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants were rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each of the 10 items was scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity for a total possible score of 0 (best) to 60 (worst). A negative change from Baseline indicates improvement.

    Time frame: Baseline (Week 0) to Week 6

Secondary outcomes

  1. Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score at Week 6

    The Clinical Global Impressions-Severity (CGI-S) is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of other participants the physician has observed. The participant was rated on a scale from 1 to 7, with 1 indicating a "normal state" and 7 indicating "among the most extremely ill participants." A negative change from Baseline indicates improvement.

    Time frame: Baseline (Week 0) to Week 6

07

Results

Posted Jan 30, 2019

Participant flow

Participant flow — Overall Study
MilestonePlaceboCariprazine 1.5 mgCariprazine 3.0 mg
Started163160165
Received treatment (safety population)158157165
Completed135134134
Not completed282631
Withdrew: Adverse event479
Withdrew: Lack of efficacy203
Withdrew: Withdrawal of consent638
Withdrew: Lost to follow-up576
Withdrew: Protocol violation100
Withdrew: Noncompliance with study drug332
Withdrew: Other miscellaneous reasons233
Withdrew: Did not receive treatment530

Outcome measures

PrimaryChange From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Week 6

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants were rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each of the 10 items was scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity for a total possible score of 0 (best) to 60 (worst). A negative change from Baseline indicates improvement.

Time frame:
Baseline (Week 0) to Week 6
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Week 6
score on a scalePlaceboCariprazine 1.5 mgCariprazine 3.0 mg
Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Week 6-12.6 ± 0.76-15.1 ± 0.77-15.6 ± 0.76
Statistical analysis
  • Placebo vs Cariprazine 1.5 mg · Mixed Model Repeated Measures (MMRM) · p = 0.0331 (MMRM analysis was used. Fixed factors: treatment group, pooled study center, visit, treatment-group-by-visit interaction. Covariates: Baseline value, baseline value-by-visit interaction. P-value was adjusted by matched parallel gatekeeping procedure.) · Least squares mean difference: -2.5 · 95% CI -4.6 to -0.4
  • Placebo vs Cariprazine 3.0 mg · Mixed Model Repeated Measures (MMRM) · p = 0.0103 (MMRM analysis was used. Fixed factors: treatment group, pooled study center, visit, treatment-group-by-visit interaction. Covariates: Baseline value, baseline value-by-visit interaction. P-value was adjusted by matched parallel gatekeeping procedure.) · Least squares mean difference: -3.0 · 95% CI -5.1 to -0.9
SecondaryChange From Baseline in Clinical Global Impressions-Severity (CGI-S) Score at Week 6

The Clinical Global Impressions-Severity (CGI-S) is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of other participants the physician has observed. The participant was rated on a scale from 1 to 7, with 1 indicating a "normal state" and 7 indicating "among the most extremely ill participants." A negative change from Baseline indicates improvement.

Time frame:
Baseline (Week 0) to Week 6
Reported as:
Least squares mean · score on a scale
Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score at Week 6
score on a scalePlaceboCariprazine 1.5 mgCariprazine 3.0 mg
Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score at Week 6-1.3 ± 0.09-1.6 ± 0.10-1.6 ± 0.09
Statistical analysis
  • Placebo vs Cariprazine 1.5 mg · Mixed Model Repeated Measures (MMRM) · p = 0.0714 (MMRM analysis was used. Fixed factors: treatment group, pooled study center, visit, treatment-group-by-visit interaction. Covariates: Baseline value, baseline value-by-visit interaction. P-value was adjusted by matched parallel gatekeeping procedure.) · Least squares mean difference: -0.2 · 95% CI -0.5 to 0.0
  • Placebo vs Cariprazine 3.0 mg · Mixed Model Repeated Measures (MMRM) · p = 0.0662 (MMRM analysis was used. Fixed factors: treatment group, pooled study center, visit, treatment-group-by-visit interaction. Covariates: Baseline value, baseline value-by-visit interaction. P-value was adjusted by matched parallel gatekeeping procedure.) · Least squares mean difference: -0.3 · 95% CI -0.5 to -0.0

Adverse events

Collected over First dose to 30 days past last dose (Up to 80 Days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/158 (0%)2/158 (1.3%)43/158 (27.2%)
Cariprazine 1.5 mg0/157 (0%)2/157 (1.3%)48/157 (30.6%)
Cariprazine 3.0 mg0/165 (0%)2/165 (1.2%)62/165 (37.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboCariprazine 1.5 mgCariprazine 3.0 mg
Iron deficiency anaemiaBlood and lymphatic system disorders0/1581/1570/165
AsthmaRespiratory, thoracic and mediastinal disorders0/1581/1570/165
Abdominal painGastrointestinal disorders1/1580/1570/165
Chronic tonsillitisInfections and infestations1/1580/1570/165
Bipolar disorderPsychiatric disorders0/1580/1571/165
Suicidal ideationPsychiatric disorders0/1580/1571/165
Most frequent other events
Most frequent other events
EventPlaceboCariprazine 1.5 mgCariprazine 3.0 mg
NauseaGastrointestinal disorders1/1586/15715/165
HeadacheNervous system disorders13/1587/15712/165
InsomniaPsychiatric disorders11/1587/15712/165
RestlessnessPsychiatric disorders6/1582/15712/165
AkathisiaNervous system disorders5/15810/1579/165
Dry mouthGastrointestinal disorders9/1586/1573/165
DizzinessNervous system disorders3/1588/1576/165
SomnolenceNervous system disorders3/1588/1576/165
SedationNervous system disorders2/1588/1575/165

Baseline characteristics

All enrolled participants who were randomized to receive the double-blind treatment.

Age, Continuous
Age, Continuous(years)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgTotal
Mean43.9 (18 to 65)42.6 (18 to 65)41.9 (19 to 64)42.8 (18 to 65)
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgTotal
Female9410194289
Male695971199
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgTotal
White118126126370
Black or African American392937105
Asian3205
American Indian or Alaska Native1113
Native Hawaiian or Other Pacific Islander2002
Multiple0213
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgTotal
Hispanic or Latino13151442
Not Hispanic or Latino150145151446
Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Baseline
Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Baseline(score on a scale)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgTotal
Mean30.3 ± 4.530.6 ± 4.231.1 ± 4.830.7 ± 4.5
Clinical Global Impressions-Severity (CGI-S) Score at Baseline
Clinical Global Impressions-Severity (CGI-S) Score at Baseline(score on a scale)PlaceboCariprazine 1.5 mgCariprazine 3.0 mgTotal
Mean4.5 ± 0.54.5 ± 0.54.5 ± 0.54.5 ± 0.5
08

Study locations

74 sites
  • Arkansas Psychiatric Clinic Clinical Research Trials PA
    Little Rock, Arkansas 72211, United States
  • ATP Clinical Research, Inc.
    Costa Mesa, California 92626, United States
  • Synergy San Diego
    Escondido, California 92025, United States
  • Integrated Medical and Behavioral Associates
    Glendale, California 91204, United States
  • Apostle Clinical Trials, Inc.
    Long Beach, California 90813, United States
  • Pacific Research Partners, LLC
    Oakland, California 94612, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Schuster Medical Research Institute
    Sherman Oaks, California 91403, United States
  • Viking Clinical Research
    Temecula, California 92591, United States
  • Pacific Clinical Research Medical Group
    Upland, California 91786, United States
  • Comprehensive Psychiatric Care
    Norwich, Connecticut 06360, United States
  • CNS Healthcare
    Jacksonville, Florida 32256, United States
  • Clinical Neuroscience Solutions, Inc
    Orlando, Florida 32801, United States
  • Olympian Clinical Research
    Tampa, Florida 33609, United States
  • Radiant Research
    Atlanta, Georgia 30328, United States
  • iResearch Atlanta, LLC
    Decatur, Georgia 30030, United States
  • Northwest Behavioral Research Center
    Marietta, Georgia 30060, United States
  • Carman Research
    Smyrna, Georgia 30080, United States
  • Psychiatric Medicine Associates, L.L.C
    Skokie, Illinois 60076, United States
  • Neuroscience Research Institute Inc.
    Winfield, Illinois 60190, United States
  • St. Charles Psychiatric Associates - Midwest Research Group
    Saint Charles, Missouri 63304, United States
  • Altea Research Institute
    Las Vegas, Nevada 89102, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Neurobehavioral Research, Inc.
    Cedarhurst, New York 11516, United States
  • Medical & Behavioral Health Research, PC
    New York, New York 10023, United States
  • Neuro-Behavioral Clinical Research
    Canton, Ohio 44718, United States
  • Patient Priority Clinical Sites
    Cincinnati, Ohio 45215, United States
  • Ohio State University Department of Psychiatry
    Columbus, Ohio 43210, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73103, United States
  • Sooner Clinical Research
    Oklahoma City, Oklahoma 73112, United States
  • Oregon Center for Clinical Investigations, Inc.
    Portland, Oregon 97214, United States
  • Oregon Center for Clinical Investigations
    Salem, Oregon 97301, United States
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18104, United States
  • Lincoln Research, LLC
    Lincoln, Rhode Island 02865, United States
  • Clinical Neuroscience Solutions
    Memphis, Tennessee 38119, United States
  • Red Oak Psychiatry Associates, PA
    Houston, Texas 77090, United States
  • Houston Clinical Trials, LLC
    Houston, Texas 77098, United States
  • Research Across America
    Plano, Texas 75093, United States
  • Family Psychiatry of The Woodlands
    The Woodlands, Texas 77381, United States
  • Alliance Research Group
    Richmond, Virginia 23230, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Core Clinical Research
    Kirkland, Washington 98033, United States
  • Summit Research Network Seattle
    Seattle, Washington 98104, United States
  • Mental Health Centre 'Prof. Dr. Ivan Temkov', EOOD
    Burgas, 8000, Bulgaria
  • SPH - Kardzhali, EOOD
    Kardzhali, 6600, Bulgaria
  • MHAT "Dr. Hristo Stambolski", EOOD
    Kazanlak, 6100, Bulgaria
  • State Psychiatric Hospital - Lovech
    Lovech, 5500, Bulgaria
  • UMHAT 'Dr. Georgi Stranski', EAD
    Pleven, 5800, Bulgaria
  • UMHAT "Sv. Georgi", EAD
    Plovdiv, 4000, Bulgaria
  • MHC - Ruse, EOOD
    Ruse, 7003, Bulgaria
  • MHATNP "Sv.Naum", EAD
    Sofia, 1113, Bulgaria
  • UMHAT "Alexandrovska" EAD
    Sofia, 1431, Bulgaria
  • Military Medical Academy - MHAT - Sofia
    Sofia, 1606, Bulgaria
  • Medical Centre "Doverie" AD
    Sofia, 1632, Bulgaria
  • MHAT-Targovishte, AD
    Targovishte, 7700, Bulgaria
  • DCC "Mladost M" - Varna, OOD
    Varna, 9020, Bulgaria
  • Marienthal Center of Psychiatry and Psychology
    Tallinn, 10617, Estonia
  • West Tallinn Central Hospital
    Tallinn, 13517, Estonia
  • Tartu University Hospital
    Tartu, 50417, Estonia
  • Romuvos klinika, UAB
    Kaunas, 44279, Lithuania
  • Neuromeda, JSC
    Kaunas, 50185, Lithuania
  • Republican Kaunas Hospital Psychiatry Clinic Mariu Division, Public Institution
    Kaunas, 53136, Lithuania
  • Hospital of Lithuanian University of Health Sciences Kaunas Clinics
    Kaunas, LT-50009, Lithuania
  • 232Antakalnis Psychiatric Consultation Center, Public Institution
    Vilnius, 10204, Lithuania
  • Podlaskie Centrum Psychogeriatrii
    Białystok, 15-756, Poland
  • Przychodnia Srodmiescie Sp. z o. o.
    Bydgoszcz, 85-080, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdańsk, 80-214, Poland
  • Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS
    Leszno, 64-100, Poland
  • Clinical Best Solutions
    Lublin, 20-045, Poland
  • Specjalistyczna Praktyka Lekarska Marek Domański
    Lublin, 20-442, Poland
  • NZOZ Syntonia
    Pruszcz Gdański, 83-000, Poland
  • Torunskie Centrum Psychiatrii Neuromed
    Toruń, 87-100, Poland
  • INSPIRA Clinical Research
    San Juan, 00918, Puerto Rico
09

References and documents

Publications

  • Citrome L, Yatham LN, Patel MD, Barabassy A, Hankinson A, Earley WR. Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression. J Affect Disord. 2021 Jun 1;288:191-198. doi: 10.1016/j.jad.2021.03.076. Epub 2021 Mar 31. PubMed 33915374 ↗
  • Thase ME, Harrington A, Calabrese J, Montgomery S, Niu X, Patel MD. Evaluation of MADRS severity thresholds in patients with bipolar depression. J Affect Disord. 2021 May 1;286:58-63. doi: 10.1016/j.jad.2021.02.043. Epub 2021 Feb 20. PubMed 33677183 ↗
  • Yatham LN, Vieta E, McIntyre RS, Jain R, Patel M, Earley W. Broad Efficacy of Cariprazine on Depressive Symptoms in Bipolar Disorder and the Clinical Implications. Prim Care Companion CNS Disord. 2020 Sep 17;22(5):20m02611. doi: 10.4088/PCC.20m02611. PubMed 32942346 ↗
  • Earley WR, Burgess M, Rekeda L, Hankinson A, McIntyre RS, Suppes T, Calabrese JR, Yatham LN. A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression. J Affect Disord. 2020 Feb 15;263:386-395. doi: 10.1016/j.jad.2019.11.098. Epub 2019 Nov 22. PubMed 31969269 ↗
  • Earley W, Burgess MV, Rekeda L, Dickinson R, Szatmari B, Nemeth G, McIntyre RS, Sachs GS, Yatham LN. Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study. Am J Psychiatry. 2019 Jun 1;176(6):439-448. doi: 10.1176/appi.ajp.2018.18070824. Epub 2019 Mar 8. PubMed 30845817 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Jul 2017, 16 months.

Results were first posted in Jan 2019, 1 year 6 months after primary completion. A results delay was requested in Jul 2018.

Of 29 industry-sponsored phase 3 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's 16 months is below that.

Counting every sponsor, half of 43 studies reached it within 37 months; a quarter within 21 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2016
First posted
Feb 1, 2016
StartActual
Mar 17, 2016
Primary completionActual
Jul 19, 2017
CompletionActual
Jul 19, 2017
Results delay requested
Jul 19, 2018
Results first posted
Jan 30, 2019
Last update
Jan 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02670551
Responsible party
Sponsor
First posted
Feb 1, 2016
Start date
Mar 17, 2016
Primary completion
Jul 19, 2017
Completion
Jul 19, 2017
Results posted
Jan 30, 2019
Last update
Jan 30, 2019

Study contacts

Clincial Director
study director · Forest Research Institute, Inc., an affiliate of Allergan, plc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion